Erratum: Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes. (Diabetes Care, 2022, 45, 2189–2201)

Abstract

In the article cited above, the affiliation for author Marjana Marinac appeared incorrectly due to a journal composition error; Dr. Marinac’s correct affiliation is JDRF International, New York, NY. Additional typographical errors introduced during production have also been corrected. In Table 1, the term “β cell” was used instead of “β-cell” three times. The correct table text is “β-cell–directed therapies,” “β-cell survival,” and “β-cell secretory capacity.” In Fig. 1, upper right quadrant, the heading appeared as “Trial Risk.” The correct heading is “Trial Risks.” In Table 1, minor formatting and language edits have been made for clarity and consistency within columns. In Duality of Interest, the following statement was given for author Randy L. Anderson: “R.L.A. was a JDRF board director at the time of ideation of the manuscript and has since become an employee of Provention Bio, Inc.” It would be more accurate to state, “R.L.A. was a JDRF board director at the time of ideation of the manuscript and is a consultant to Provention Bio, Inc.” The online version of the article (https://doi.org/10.2337/dc22-0308) has been updated to reflect these changes.